Chronic Neuropathic Pain Pipeline Analysis Report 2025

Chronic neuropathic pain is a condition caused by damage or disease affecting the somatosensory nervous system. According to the International Association for the Study of Pain (IASP), neuropathic pain affects approximately 7-10% of the global population. According to the chronic neuropathic pain pipeline analysis by Expert Market Research, the therapeutic landscape includes tricyclic antidepressants, SNRIs, and gabapentinoids, with over 100 novel drugs in development targeting unmet patient needs. Growing focus on non-opioid therapies, precision medicine, and innovative delivery mechanisms is expected to drive substantial growth in the coming years, reflecting rising prevalence and increasing healthcare awareness.

Report Coverage

The Chronic Neuropathic Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic neuropathic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic neuropathic pain. The chronic neuropathic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic neuropathic pain treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic neuropathic pain.

Chronic Neuropathic Pain Pipeline Outlook

Chronic neuropathic pain is a persistent condition caused by damage or dysfunction in the peripheral or central nervous system. It occurs when nerve signaling becomes abnormal, often triggered by inflammation, injury, or metabolic disorders, resulting in burning, tingling, or shooting pain that can severely affect quality of life.

Chronic neuropathic pain treatments include anticonvulsants, antidepressants, topical agents, and emerging neuromodulation therapies aimed at reducing abnormal nerve signaling and managing symptoms effectively. In July 2025, Monash University researchers reported a promising chronic neuropathic pain drug pipeline candidate targeting the adenosine A1 receptor. These selective positive allosteric modulators enhance receptor activity, offering pain relief with minimal cardiac side effects.

Chronic Neuropathic Pain Epidemiology

According to the International Association for the Study of Pain, neuropathic pain affects approximately 7-10% of the general population. In Europe, the prevalence is estimated at 7%-8%, as reported by Anas Hamdan et al., 2024. Globally, chronic pain impacts 2%-40% of individuals, with 27%-58% of people aged 65 years and older experiencing this condition, according to Ambrish Singh et al., 2024. These trends highlight the ongoing need for novel therapeutic developments in the chronic neuropathic pain pipeline.

Chronic Neuropathic Pain - Pipeline Therapeutic Assessment

This section of the report covers the analysis of chronic neuropathic pain drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The chronic neuropathic pain pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Chronic Neuropathic Pain Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 35%, covers a major share of the total chronic neuropathic pain clinical trials. It is followed by phase I and phase IV, each at 23%. Phase III accounts for 15.38%. This strong distribution across clinical phases indicates robust development activity, suggesting a promising future for innovative therapies and potential market growth.

Chronic Neuropathic Pain Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the chronic neuropathic pain pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The chronic neuropathic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic neuropathic pain. Selective peripheral sodium channel blockers are gaining attention in the chronic neuropathic pain pipeline. For example, VX-548, a Nav1.8 inhibitor developed by Vertex Pharmaceuticals, is under evaluation for reducing post-surgical and chronic nerve pain. Additionally, other Nav1.7-targeting compounds are being investigated to modulate dorsal root ganglion neuron hyperactivity, offering potential non-addictive, non-sedating alternatives for patients unresponsive to current therapies.

Chronic Neuropathic Pain Clinical Trials - Key Players

The report for the chronic neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic neuropathic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic neuropathic pain clinical trials:

• Beijing Tide Pharmaceutical Co., Ltd.
• Sangamo Therapeutics
• Eli Lilly and Company
• Hypersound Medical Inc.
• Contineum Therapeutics
• iN Therapeutics Co., Ltd.
• GlaxoSmithKline
• Sanofi
• Pfizer
• Endo Pharmaceuticals
• Janssen Pharmaceutical K.K.
• UCB Pharma

Chronic Neuropathic Pain - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic neuropathic pain drug candidates.

Drug: TRD205

TRD205 is a first-in-class AT2R antagonist developed by Beijing Tide Pharmaceutical Co., Ltd. This Phase II, multicenter, randomized, double-blind, placebo-controlled, dose-finding study is evaluating the efficacy, safety, and pharmacokinetics of TRD205 tablets in treating chronic postoperative neuralgia. The study is examining multiple dose regimens to determine optimal therapeutic outcomes. TRD205 is designed as a non-opioid therapy, selectively blocking AT2R activation, offering effective pain relief while minimizing risks of addiction and respiratory depression.

Genetic: ST-503

ST-503 is a gene therapy drug sponsored by Sangamo Therapeutics, designed to target chronic neuropathic pain associated with idiopathic small fiber neuropathy (iSFN). This Phase 1 study is examining the safety and tolerability of a single intrathecal dose of ST-503. The drug delivers an engineered zinc finger repressor via an AAV vector to selectively suppress the SCN9A gene, reducing Nav1.7 sodium channels in sensory neurons and potentially alleviating refractory pain. The trial is expected to commence in October 2025 with estimated completion in July 2028, enrolling 27 participants.

Key Questions Answered in the Chronic Neuropathic Pain Pipeline Insight Report

• Which companies/institutions are leading the chronic neuropathic pain drug development?
• Which company is leading the chronic neuropathic pain pipeline development activities?
• What is the current chronic neuropathic pain commercial assessment?
• What are the opportunities and challenges present in the chronic neuropathic pain pipeline landscape?
• What is the efficacy and safety profile of chronic neuropathic pain pipeline drugs?
• Which company is conducting major trials for chronic neuropathic pain drugs?
• Which companies/institutions are involved in chronic neuropathic pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in chronic neuropathic pain?

Reasons To Buy This Report

The Chronic Neuropathic Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic neuropathic pain collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.